Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
5
Neutral
1
Bullish
8
Bearish
37
Neutral
1
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Bearish
5
Neutral
1
Bullish
8
Bearish
5
Neutral
1
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Investor Presentation
Q4 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q2 FY21
Investor Presentation
Q4 FY20
Investor Presentation
Q4 FY18
Investor Presentation
Q3 FY18
Investor Presentation
Q2 FY18
Lasa Supergenerics Limited is an Indian manufacturer of Active Pharmaceutical Ingredients (APIs) focused on veterinary and human healthcare chemical products, vertically integrated from discovery through bulk production, with facilities in the Konkan region of Maharashtra and stated strengths in catalyst chemistry and anthelmintic/veterinary APIs.
Financially, FY2026 shows severe stress: revenue from operations fell to Rs. 2,514.07 lakhs versus Rs. 14,244.81 lakhs a year earlier, and the company reported a net loss after tax of Rs. (3,409.03) lakhs; the audit report contains a qualified opinion related to asset impairment and intangible asset valuation, signalling material accounting uncertainty.
Operations have been materially disrupted by an uninsured fire at the Lote Parshuram mother unit on 18 May 2025, which management says halted production across units, produced exceptional losses recognized previously, impeded physical inspection due to labour unrest, and triggered suspension of government grant recognition until operations are restored.
Strategically the company is investing in a brownfield expansion at Chiplun to add 20 MT capacity for oxyclozanide, described as a blockbuster veterinary product with strong global demand and high entry barriers; management also contemplates contract manufacturing and leasing options to restore revenue while recovery plans are evaluated.
Contingent liabilities and regulatory risk are material: auditors flagged unresolved GST demand notices aggregating to Rs. 3,810.93 lakhs, mismatches in GST filings, and absence of bank confirmations on dormant accounts; these amplify going-concern and cash-flow uncertainty while the company seeks funding and legal resolutions.
Pharmaceuticals & Biotechnology
Pharmaceuticals
27 Cr
Low Risk
-1.6
34.8
—
0.5
12.46
5.13
Sales CAGR
Profit CAGR
ROE
ROCE
Lasa Supergenerics Ltd (LASA) is currently trading at 5.29 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Lasa Supergenerics Limited is an Indian manufacturer of Active Pharmaceutical Ingredients (APIs) focused on veterinary and human healthcare chemical products, vertically integrated from discovery through bulk production, with facilities in the Konkan region of Maharashtra and stated strengths in catalyst chemistry and anthelmintic/veterinary APIs. Financially, FY2026 shows severe stress: revenue from operations fell to Rs. 2,514.07 lakhs versus Rs. 14,244.81 lakhs a year earlier, and the company reported a net loss after tax of Rs. (3,409.03) lakhs; the audit report contains a qualified opinion related to asset impairment and intangible asset valuation, signalling material accounting uncertainty. Operations have been materially disrupted by an uninsured fire at the Lote Parshuram mother unit on 18 May 2025, which management says halted production across units, produced exceptional losses recognized previously, impeded physical inspection due to labour unrest, and triggered suspension of government grant recognition until operations are restored. Strategically the company is investing in a brownfield expansion at Chiplun to add 20 MT capacity for oxyclozanide, described as a blockbuster veterinary product with strong global demand and high entry barriers; management also contemplates contract manufacturing and leasing options to restore revenue while recovery plans are evaluated. Contingent liabilities and regulatory risk are material: auditors flagged unresolved GST demand notices aggregating to Rs. 3,810.93 lakhs, mismatches in GST filings, and absence of bank confirmations on dormant accounts; these amplify going-concern and cash-flow uncertainty while the company seeks funding and legal resolutions.
Over the past 52 weeks, Lasa Supergenerics Ltd has traded between a low of ₹5.13 and a high of ₹12.46. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Lasa Supergenerics Ltd has a market capitalization of approximately 26.50. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Lasa Supergenerics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -1.60 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 26.50 Cr, Lasa Supergenerics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Lasa Supergenerics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Lasa Supergenerics Ltd is -1.60. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board meeting to consider and approve unaudited Q1 FY27 results (quarter ended June 30, 2026) is scheduled for August 14, 2026.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
21.40 | 30 Cr | 5.09 | 0.80 | 0.00 | 15.82 | 19.17 | 11.89 | ||
39.00 | 29 Cr | 9.65 | 0.89 | 0.00 | 9.20 | 12.30 | 3.24 | ||
19.98 | 29 Cr | 45.52 | 1.14 | 0.00 | 2.76 | 0.90 | — | ||
34.13 | 27 Cr | 12.78 | 2.73 | 0.00 | 25.62 | 29.29 | 8.47 | ||
5.29 | 27 Cr | -1.60 | 0.53 | 0.00 | -26.30 | -22.21 | -24.96 | ||
26.10 | 25 Cr | 9.92 | 1.30 | 0.00 | 13.09 | 13.74 | 4.84 | ||
| Median: 6 Co. | — | 23.75 | 28 Cr | 9.79 | 1.01 | 0.00 | 11.14 | 13.02 | 4.84 |
